Notice

Selected for New Product Development Project with Purchase Condition from SMEs

Selected for the Anyfusion drug library cylinder pump development project by the Ministry of SMEs and Startups for the Free Competition for New Product Development Project with Purchase Condition

The Anyfusion drug library cylinder pump development project was selected for the Ministry of SMEs and Startups' free competition for new product development projects with purchase conditions and will receive a project cost of 500 million won for two years.

Drug library program, which maximizes the therapeutic effect by increasing the accuracy of drug injection by pharmacokinetics with different specific gravity, concentration and nature of each drug, is a smart drug injection pump that is basically used in most countries except Korea (medical insurance is not recognized).

Drug library pump is the pump whose accuracy was compared with Anyfusion cylinder pump when the FDA reviewed STeP. The comparison was made because the original technology itself cannot guarantee accuracy, and even if the drug library program is embedded in the existing pump, the accuracy is not improved, so safety and effectiveness are not guaranteed. Anyfusion cylinder pump based on cylinder cartridge, which is the core original technology, has the world's best accuracy even without a drug library program embedded, and the only real-time ±0%, which is why it was selected by the FDA as an innovative medical device in STeP. With the drug library program embedded in it, it is the most ideal drug infusion pump with guaranteed safety and effectiveness, and there is no comparison in terms of performance.

Drug library pump is the pump demanded by most buyers at international exhibitions. In addition, in this new product development, the level of dustproof and waterproof required by developed countries is developed to the highest level from IPX 0 (dustproof) and 2 (waterproof) to IPX 2 (dustproof) and 4 (waterproof). 

Anyfusion ACPi system for rapidly dispensing 5FU and Cisplatin, the most toxic anti-cancer drugs with the highest number of dispensations per day, required by CSTD fusion in Spain and Italy, was tested by collecting and testing the parts required for the product to meet the performance requested by hospital dispensing departments in both countries, With the results of dispensing more than 40 dispensations per hour for the same anti-cancer drug with an accuracy of ±1%, and 4 minutes for simultaneous filling of PCA balloon anti-cancer drug and 300 ml of fluid with an accuracy of ±0%, we confirmed that it is the fastest in the world, with more than 300 dispensations per day, and the ideal equipment with the optimal conditions of the specifications required by the anti-cancer (injection) drug dispensing field in Spain and Italy, as well as Korea and all countries, where the equipment price is reasonable.

We decided to demo it in a number of domestic university hospitals in August, and it is judged that the market response will be decided whether the quantum jump will be made as a result of the demo. In Spain, Italy, and Kuwait, where we shared the data, we were satisfied and asked to get CE MDR certification as soon as possible to supply the product. Anyfusion cylinder pump is an infusion pump and syringe pump that has been used for decades, and the world's major companies have established a solid network and done marketing, so even if the safety and effectiveness are excellent, it takes time to sell, but there is no competing product with the performance required by customers, and there is no manpower shortage due to the risk of dispensing, so the necessary equipment is the Anyfusion ACPi system, which requires urgency due to serious business reasons.

If the market for the Anyfusion ACPi system is formed as planned, we would like to expand the market for the Anyfusion cylinder pump by bundle marketing with the Anyfusion drug library cylinder pump that will be developed.

Thank you.

Next Completed a contract new product development project with SMEs
Prev Updates following the June presentations at Sevilla, Spain, and Catania, Italy